# A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

> **NCT03145909** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 19 (actual)

## Conditions studied

- Advanced Solid Tumors Cancer

## Interventions

- **DRUG:** ABBV-176

## Key facts

- **NCT ID:** NCT03145909
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-03
- **Primary completion:** 2018-11-27
- **Final completion:** 2018-11-27
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Safety
- **Last updated:** 2018-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03145909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03145909, "A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03145909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*